Standard Biotools (LAB) Receivables (2010 - 2026)

Standard Biotools (LAB) has 17 years of Receivables data on file, last reported at $16.6 million in Q1 2026.

• On a quarterly basis, Receivables fell 53.11% year-over-year to $16.6 million in Q1 2026; TTM through Mar 2026 was $16.6 million, a 53.11% decrease from a year earlier, with the FY2025 full-year figure at $13.7 million, down 8.57% from the prior year.
• Receivables for Q1 2026 stood at $16.6 million, up from $13.7 million in the prior quarter.
• Over the last five years, Receivables for LAB reached as high as $36.0 million in Q1 2024 and fell as low as $10.9 million in Q2 2022.
• Historically, Receivables has averaged $20.0 million across 5 years, with a median of $16.6 million in 2023.
• Across the five-year window, Receivables surged 148.29% in 2024 and sank 61.67% in 2025, its largest moves.
• Year by year, Receivables stood at $17.3 million in 2022, then rose by 13.77% to $19.7 million in 2023, then fell by 23.7% to $15.0 million in 2024, then decreased by 8.57% to $13.7 million in 2025, then climbed by 21.31% to $16.6 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $16.6 million in Q1 2026, $13.7 million in Q4 2025, and $13.5 million in Q3 2025.